1h Free Analyst Time
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Cholesteryl Ester Transfer Protein - Drugs In Development, 2022, outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Central Nervous System and Infectious Disease which include indications Dyslipidemia, Acute Coronary Syndrome, Alzheimer's Disease, Atherosclerosis, Cardiovascular Disease, Coronavirus Disease 2019 (COVID-19), Diabetes, Heterozygous familial hypercholesterolemia (heFH) and Hypercholesterolemia.
Furthermore, this report also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Co
- Chong Kun Dang Pharmaceutical Corp
- DalCor Pharmaceuticals Inc
- NewAmsterdam Pharma BV
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
- CKD-508 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dalcetrapib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HL-16 - Drug Profile
- Product Description
- Mechanism Of Action
- obicetrapib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit CETP for Cardiovascular Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
- Product Description
- Mechanism Of Action
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
- Featured News & Press Releases
- Jun 06, 2022: NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals
- May 19, 2022: NewAmsterdam pharma to present at upcoming medical conferences new post-Hoc analyses from phase 2 ROSE trial of obicetrapib in patients with dyslipidemia
- May 11, 2022: New Meta-Analysis in European Heart Journal’s Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors’ Role in Reduction of Diabetes Risk
- Apr 05, 2022: NewAmsterdam Pharma doses first patient in phase 2 trial of Obicetrapib in combination with Ezetimibe as an adjunct to high-intensity statin therapy
- Mar 01, 2022: NewAmsterdam Pharma doses first patient in PREVAIL, the cardiovascular outcomes trial of obicetrapib in adults with atherosclerotic cardiovascular disease (ASCVD)
- Feb 14, 2022: New review article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) inhibition’s role in reducing cardiovascular disease risk
- Jan 04, 2022: NewAmsterdam Pharma doses first patient in phase 3 BROADWAY trial of obicetrapib in adults with heterozygous familial hypercholesterolemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD)
- Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
- Nov 08, 2021: NewAmsterdam Pharma announces ROSE phase 2 trial results accepted for Featured Science Presentation at 2021 AHA Scientific Sessions
- Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
- Jul 27, 2020: DalCor announces dal-GenE trial continues with final data expected in the first half of 2021
- Jan 27, 2020: Dalcor announces Dal-gene trial to continue as planned following interim futility analysis
- Dec 17, 2018: Dalcor announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease
- Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
- Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Pipeline by DalCor Pharmaceuticals Inc, 2022
- Pipeline by NewAmsterdam Pharma BV, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Chong Kun Dang Pharmaceutical Corp
- DalCor Pharmaceuticals Inc
- NewAmsterdam Pharma BV
